Tevimbra® Approved in Belgium for Advanced Gastric and Esophageal Cancers
gastric cancer remains a notable health challenge in Europe, ranking as the fourth leading cause of cancer death among men and the fifth among women. Approximately 82,000 new cases and 52,000 deaths occur annually across the continent. European Cancer Information System Recently, BeOne Biologics announced the launch of Tevimbra® (tislelizumab) in Belgium, offering a new treatment option for patients with frist-line esophageal squamous cell carcinoma and gastric cancer.
Understanding Gastric and Esophageal Cancers
Gastric cancer, often referred to as stomach cancer, develops in the lining of the stomach. Esophageal cancer, conversely, originates in the esophagus, the tube connecting the throat to the stomach. Esophageal squamous cell carcinoma is a subtype of esophageal cancer that begins in the flat cells lining the esophagus. Both cancers can be aggressive and are frequently enough diagnosed at later stages, making treatment more challenging. American Cancer Society – Stomach Cancer American Cancer Society – Esophageal Cancer
Tevimbra®: A New Immunotherapy Option
Tevimbra® is an anti-PD-1 monoclonal antibody. This means it’s a type of immunotherapy that works by blocking the PD-1 protein on immune cells. PD-1 acts as a “checkpoint,” preventing the immune system from attacking cancer cells. By blocking PD-1, Tevimbra® helps to unleash the immune system to recognize and destroy cancer cells. National Cancer Institute – Immunotherapy
The approval in Belgium allows Tevimbra® to be used in combination with chemotherapy as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma,and also for patients with esophageal squamous cell carcinoma,after progression with platinum-based chemotherapy.
expert Perspective on New Treatment Options
Professor Eric Van Cutsem, a gastroenterologist and digestive oncologist at the University Hospital of Leuven (UZ Leuven), emphasizes the importance of new therapies. “Cancer remains one of the biggest public health challenges in Belgium, and we still lack therapeutic solutions for certain patients. Each new therapy is an additional alternative for clinical situations where options might potentially be limited. They allow us to further adapt treatments and hope for better results for patients who need them the most.” BeOne Biologics Press Release
Clinical Trial Data Supporting Tevimbra®
The approval of Tevimbra® is based on positive results from clinical trials, including the Phase 3 RESONATE study.This study demonstrated that Tevimbra® in combination with chemotherapy significantly improved overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma compared to chemotherapy alone. BeOne Biologics – RESONATE Study
Future Outlook for Gastric and Esophageal Cancer treatment
The introduction of Tevimbra® represents a step forward in the treatment of these challenging cancers. Ongoing research continues to explore new immunotherapy combinations, targeted therapies, and surgical techniques to improve outcomes for patients. Early detection thru screening programs and continued advancements in treatment strategies are crucial in reducing the burden of gastric and esophageal cancers in Belgium and across Europe.
Worth a look